Please assess the completion status of the following clinical trial:

Trial Title: Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients first time diagnosed with breast cancer (stage I, II, III, or IV) between ages 18 and 75 (both inclusive).~* Patients with a moderate-severe level of emotional distress who meet the diagnostic criteria for major depression for at least two weeks or adjustment disorder with depressive mood for at least two months, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria (DSM-V), during the twelve months following the diagnose of breast cancer.~* Informed Consent Form Signature~Exclusion Criteria:~* Women who are pregnant or breastfeeding.~* Suicide risk.~* Metastatic brain disease.~* Personal History of oncological disease.~* Personal History of serious somatic disease (cardiac, hepatic, respiratory, endocrinological, neurological and haematological).~* Personal History of organic brain disorder, substance abuse/dependence.~* Personal History of psychotic disorder, bipolar disorder and/or mental retardation.~* Contraindications of citalopram treatment.~* Taking antidepressants after the breast cancer diagnosis.~* Psychotherapy treatment after breast cancer diagnosis .

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Citalopram 20-40 mg (Type: EXPERIMENTAL): Participants received citalopram 20 mg tablet once or twice daily for 12 weeks.
- Psychotherapy (Type: EXPERIMENTAL): Participants received one psychotherapy session weekly for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).